{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:26:07Z","timestamp":1790738767225,"version":"4.1.0"},"reference-count":8,"publisher":"SLACK, Inc.","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:p>The author presents a retrospective case report of a 54-year-old male with ipilimumab (Yervoy; Bristol-Myers Squibb, New York City, NY)-induced Vogt-Koyanagi-Harada Disease (VKH), which consisted of uveitis, optic neuritis, and choroiditis that was successfully treated with oral dexamethasone. The patient demonstrated resolution of uveitis, optic neuritis, and choroiditis 1 month following initiation of oral dexamethasone. Ipilimumab is a recently approved therapy for malignant melanoma. Reports have identified that VKH disease is a potential side effect of the medication. Oral dexamethasone is a safe and effective treatment for this side effect of the medication.<\/jats:p>\n          <jats:p>\n            <jats:bold>\n              [\n              <jats:italic>Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n              . 2017;48:928\u2013931.]\n            <\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/23258160-20171030-09","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T20:40:46Z","timestamp":1510260046000},"page":"928-931","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone"],"prefix":"10.3928","volume":"48","author":[{"given":"Matthew T.","family":"Witmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70122-1"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611299"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00925-4"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0b013e31824f7130"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000066"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200411000-00008"},{"key":"e_1_3_1_9_2","volume-title":"Ipilimumab (Yervoy) [package insert]","year":"2011","unstructured":"Ipilimumab (Yervoy) [package insert]. New York City, NY: Bristol-Meyers-Squibb; 2011."}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.healio.com\/doiresolver?doi=10.3928\/23258160-20171030-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T08:08:19Z","timestamp":1683101299000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20171030-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.3928\/23258160-20171030-09"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20171030-09","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}